Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)

Summary

Clinical trial aimed at evaluating whether a single infusion of tocilizumab, a medication that blocks the action of an inflammatory molecule called interleukin-6 (IL-6), can reduce symptoms of treatment-resistant major depression compared to placebo in non-hospitalized patients.

Timeline

Start

2026-07-01

Primary completion

2028-07-01

Completion

2028-07-01

Publications

• Portal PHG, Peixoto GN, de Matos MR, da Silva LCN, Alexandrino GB, Dutra PHG, Carniel BP, da Rocha NS. Add-on tocilizumab versus placebo for resistant major depression in psychiatric outpatients with low-grade inflammation in a tertiary public hospital in Southern Brazil: randomised triple-blind clinical trial protocol. BMJ Open. 2026 Jun 12;16(6):e111421. doi: 10.1136/bmjopen-2025-111421.

Drugs

Indications